Research & Development
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNP...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel...
ZYUS Life Sciences receives second US pain management patent
6 May 2026 - Canada-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialisation of novel non-opioid drug candidates for pa...
Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital
6 May 2026 - Citius Oncology Inc (Nasdaq:CTOR), a specialty biopharmaceutical company focused on the development and commercialisation of novel targeted oncology therapies, announced on Tuesday that i...
Alebund Pharmaceuticals completes AP301 Phase III clinical trial patient enrolment for hyperphosphataemia
6 May 2026 - Chinese biopharmaceutical company Alebund Pharmaceuticals Limited announced on Wednesday the completion of patient enrolment in the global Phase III pivotal multi-regional clinical trial ...
Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education
5 May 2026 - US biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Monday announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia ...